MiSight 1 day is a new lens developed by Coopervision. It hit the U.S. market in the spring of 2020 and is the first contact lens of its kind, receiving official approval from the FDA to not only provide vision correction but also to slow down the progression of childhood myopia.
MiSight lenses with omafilcon A are daily disposable and single-wear contact lenses indicated for the correction of myopic ametropia. With the FDA approval, they are also indicated for slowing the progression of myopia in children with non-diseased eyes requiring refractive vision correction in the range of -0.75D to -4.00D diopters and up to 0.75 diopters of astigmatism.
In an announcement, CooperVision's President Daniel G. McBride said: “We can’t overstate the importance and potential impact of this landmark decision on children’s vision, especially considering the rise in myopia’s severity and prevalence in the U.S. and worldwide. Eye care professionals who embrace this breakthrough approach will improve the quality of life and eye health for so many children”.
While traditional vision correction such as eyeglasses and contact lenses for this age group and eye condition do not slow the progression of myopia, eye care practitioners now have access to a new lens that can help their patients to slow the progression of myopia while providing the convenience of a daily-disposable contact lens.
Michele Andrews, OD, Senior Director of North America Professional and Academic Affairs for CooperVision adds: “While there is growing acknowledgment and interest in stemming myopia’s progression, there needs to be more urgency to act earlier. We believe that MiSight® 1 day will be a catalyst that helps ECPs move faster and gives rise to better ECP-parent conversations about the issue. It’s a privilege to be at the forefront of myopia management. Working alongside so many dedicated eye care professionals and passionate parents, we’re already making a meaningful difference in tackling myopia, and can now expand our efforts into the U.S.”